CARGO Therapeutics, Inc. (CRGX) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
CRGX currently has 48.1M outstanding shares. with moderate dilution risk from 18.8M authorized shares representing 39.0% potential dilution. The company has significantly diluted shareholders by 26.22% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Aug 19, 2025 |
S-3/A filing: S-3/A filing registering (i) a base prospectus for up to $300,000,000 of common stock, preferred stock, debt securities, warrants and/or units; and (ii) the sale of up to $200,000,000 of common stock under a sales agreement with TD Securities (USA) LLC. |
48M | 19M |
| Aug 19, 2025 |
S-3/A filing: This S-3/A filing registers (i) a base prospectus for the offering, issuance and sale of up to $300,000,000 of common stock, preferred stock, debt securities, warrants and/or units and (ii) the sale of up to $200,000,000 of common stock under a sales agreement with TD Securities (USA) LLC. |
48M | 19M |
| Aug 06, 2025 |
10-Q filing | 48.1M shares outstanding |
48M | 19M |
| May 08, 2025 |
10-Q filing | 47.9M shares outstanding |
48M | 19M |
| Mar 12, 2025 |
10-K filing | 45.0M shares outstanding |
45M | 19M |
| Mar 12, 2025 |
POS AM filing: This prospectus relates to the proposed resale or other disposition by the selling stockholders of up to an aggregate of 6,471,000 shares of common stock. The company is not selling any common stock under this prospectus and will not receive any proceeds from the sale by the Selling Stockholders of the Resale Shares. |
48M | 19M |
| Mar 12, 2025 |
POS AM filing: Cargo Therapeutics, Inc. files a POS AM to offer and sell up to $300,000,000 in the aggregate of common stock, preferred stock, and debt securities from time to time in one or more offerings. |
46M | 19M |
| Nov 12, 2024 |
10-Q filing | 47.7M shares outstanding |
48M | 25M |
| Aug 12, 2024 |
10-Q filing | 43.3M shares outstanding |
43M | 25M |
| Jun 17, 2024 |
S-1 filing: This S-1 filing relates to the proposed resale of up to 6,471,000 shares of common stock by selling stockholders. |
41M | 25M |
| May 14, 2024 |
10-Q filing | 41.0M shares outstanding |
41M | 19M |
| Mar 21, 2024 |
10-K filing | 39.4M shares outstanding |
39M | 19M |
| Dec 13, 2023 |
10-Q filing | 41.2M shares outstanding |
41M | 19M |
| Nov 06, 2023 |
S-1/A filing: S-1/A filing for an offering of common stock with an option to purchase additional shares, intended to fund clinical trials, research and development, and general corporate purposes. |
20M | 19M |
| Nov 01, 2023 |
S-1/A filing: This is an S-1/A filing detailing recent sales of unregistered securities, including common stock and preferred stock issuances, since January 1, 2020. |
N/A | 15M |
| Oct 20, 2023 |
S-1 filing: This is an S-1 filing related to an initial public offering, detailing executive compensation, offering terms for common stock, use of proceeds, risk factors, and financial data. |
N/A | 0 |